Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 2/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868101 | 0.80 | CRBN (0.69) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL15003335 | 0.80 | CRBN (0.69) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL13949422 | 0.79 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL10023980 | 0.79 | CRBN (0.49) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20233851 | 0.77 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL12410834 | 0.76 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL410642 | 0.74 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL571278 | 0.74 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL7581 | 0.74 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL15197560 | 0.74 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143283-B1 | Methods for treating blood-born tumors with thalidomide | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8039488-B2 | Methods and compositions for inhibition of angiogenesis | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1920773-B1 | Thalidomide and dexamethasone for the treatment of tumors | CHILDRENS MEDICAL CENTER (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7723361-B2 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide | CELGENE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7524865-B2 | Methods and compositions for treating an ocular neovascular disease | CELGENE CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7435745-B2 | Methods and compositions for inhibition of angiogenesis | CELGENE CORPORATION (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1920773-A1 | Compositions for inhibition of anglogenesis | The Children's Medical Center Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049566-A1 | Administering thalidomide in combination with dexamethasone either parenterally or orally; anticarcinogenic agents | D AMATO ROBERT J | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049566-A1 | Administering thalidomide in combination with dexamethasone either parenterally or orally; anticarcinogenic agents | PGF, HPGDS, TNF | CRBN 190/4885DDB1 86/4885IKZF3 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.